Navigation Links
DURECT to Participate in Upcoming Healthcare Conferences
Date:2/23/2012

CUPERTINO, Calif., Feb. 23, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  • James E. Brown, President and CEO, will present at the RBC Capital Markets' Global Healthcare Conference on Wednesday, February 29 at 8:00 a.m. Eastern Time.  The conference is being held at the New York Palace Hotel in New York City.  A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rbc141/drrx/.
  • James E. Brown, President and CEO, will also present at the Cowen and Company 32nd Annual Healthcare Conference on Wednesday, March 7 at 11:20 a.m. Eastern Time.  The conference is being held at the Marriott Copley Place in Boston.  A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/cowen6/drrx/.

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR™ and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.

 


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017  AOTI Inc. announced today that its fully owned ... opened a New York City Office in Yonkers, New ... Topical Wound Oxygen (TWO 2 ) homecare therapy. This new East ... Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical ... Advanced Oxygen ...
(Date:8/10/2017)... -- Physical Rehabilitation Network (PRN), acquired the long-standing outpatient rehabilitation clinic, ... . The reputable clinic will continue to be co-owned and ... staff of four clinicians. Lipkin received his doctorate in physical ... years of experience with a strong background in manual therapy. ... 10th PRN clinic in and around the Denver ...
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
Breaking Medicine Technology:
(Date:8/19/2017)... , ... August 18, 2017 , ... Western University of ... and education to launch the University’s new Center for Innovation on Wednesday, September 6, ... Education Center Lecture Hall 1, followed by a technology exhibition from 1 to 3 ...
(Date:8/19/2017)... ... , ... Curl Keeper® is excited to announce that the H2O Water Bottle ... for the second year in a row. The H2O Bottle, a refillable ultra-fine spray ... Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies in 2017. ...
(Date:8/19/2017)... Orlando, Fla. (PRWEB) , ... August 19, 2017 ... ... that Taufiq Ahmed, M.D., has joined its Orlando location as an interventional pain ... in anesthesiology, a focus on the treatment of migraine headaches, and significant experience ...
(Date:8/18/2017)... ... August ... ... For Immediate Release                Contact: Julian Teixeira, August 18, ... Sex and Relationship Advice from their Fathers , Contrary ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces ... active, healthy lifestyles and highlighting the importance of proactive eye and ear health. ... shares the latest innovations in hearing aid technology. , In this issue, ...
Breaking Medicine News(10 mins):